Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

News

10 April 2018

CANTAB Recruit software to be used in two major Phase III drug trials

​We’re pleased to announce that our CANTAB Recruit software is now established in two major Phase III trials into Alzheimer’s disease.

Did you know that patient recruitment amounts to approximately one third of the total costs in pharmaceutical clinical trials, with 80% of development programmes delayed due to unfulfilled enrolment numbers1? It’s estimated that these subsequent delays cost sponsors up to $8 million in lost revenues for each day a study is delayed2.

With the use of our CANTAB Recruit SaaS product, however, sponsors are able to rapidly scale up their recruitment efforts without requiring participants to visit a study site or take part in more invasive testing. This makes for a more cost- and time-effective recruitment process which also delivers a more patient-centric recruitment experience.

Already confirmed in 2018, our CANTAB Recruit software will be applied to two of the world's largest and most valuable drug trials to improve patient recruitment in Alzheimer's disease.

One of these trials started with an initial pilot study to assess the recruitment eligibility of 100 participants. Due to the success of the pilot, the sponsoring pharmaceutical company will now use CANTAB Recruit software to screen tens of thousands of participants globally.

There are 139 clinical trials in the Alzheimer's disease treatment development pipeline alone, a 21% increase on the previous year3,4. In response to this continues market growth, we are expanding the capabilities of our recruitment software for use in indications such as schizophrenia and depression.

Cambridge Cognition digital health software continues to enable pharmaceutical companies to collect high quality data in ways that improve R&D productivity.

CANTAB Recruit is delivering high-value participant screening directly to end-users at scale and is part of the ongoing expansion of CANTAB products from simple endpoint testing to patient finding and patient population definition. - Dr Steven Powell, CEO at Cambridge Cognition

If you're interested in learning how CANTAB Recruit can enhance the patient recruitment process for your trial, please get in touch with us for more information.

Learn more

References:

1 PharmaFile (2016). Clinical trials and their patients: The rising costs and how to stem the loss.

2 Cutting Edge Information (2004). Accelerating Clinical Trials: Budgets, Patient Recruitment and Productivity.

3 Cummings, J. et al (2017). Alzheimer’s disease drug development pipeline: 2017. Alzheimer’s & Dementia. Translational Research & Clinical Interventions, 3(3), 367–384.

4 Cummings, J. et al (2016). Alzheimer’s drug-development pipeline: 2016. Alzheimer’s & Dementia. Translational Research & Clinical Interventions, 2(4), 222–232.